Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
0.5685
+0.0232 (4.25%)
At close: Oct 2, 2026, 4:00 PM EDT
0.5585
-0.0100 (-1.76%)
After-hours: Oct 2, 2026, 7:39 PM EDT
Traws Pharma Revenue
In the year 2025, Traws Pharma had annual revenue of $2.79M with 1,134.51% growth.
Revenue (ttm)
$2.79M
Revenue Growth
+1,134.51%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
8.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.79M | 2.56M | 1,134.51% |
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
| Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
| Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
| Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
| Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
| Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
| Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
| Dec 31, 2011 | 1.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Immuron | 5.34M |
| Longeveron | 1.19M |
| Azitra | 7.50K |
| Aprea Therapeutics | 5.19K |
| Soligenix | 2.34K |
TRAW News
- 7 weeks ago - Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewsWire
- 7 weeks ago - Traws Pharma Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Traws Pharma Earnings release: Q2 2026 - Filings
- 2 months ago - Traws Pharma Transcript: AGM 2026 - Transcripts
- 3 months ago - Traws Pharma files $139.19M mixed securities shelf - TheFly
- 3 months ago - Traws Pharma Registration statement: Registration filing - Filings
- 3 months ago - Traws Pharma provides update on tivoxavir marboxil program - TheFly
- 3 months ago - Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - GlobeNewsWire